The August 2026 active multidistrict litigation update shows huge product-liability dockets alongside three major developments: Depo-Provera settlement administration, a social-media trial phase, and an $88 million Covidien mesh verdict. Multidistrict litigation, or MDL, groups similar federal lawsuits for coordinated pretrial work; readers should now watch expert rulings, trial results, appeals, and settlement participation.
This update is an August 3 snapshot, not a month-end census. The U.S. Judicial Panel on Multidistrict Litigation posts its report on each month's first business day, according to the JPML's pending-MDL page.
Table of Contents
- What the August MDL numbers actually measure
- Which active MDLs were the largest?
- Depo-Provera moved toward settlement—but litigation continues
- Trials and opt-outs show why headline results have limits
- What should plaintiffs and families watch next?
What the August MDL numbers actually measure
JPML counts "actions now pending" in active, transferred federal MDLs. Those figures do not represent the number of injured people, valid claims, settlement participants, or people eligible for compensation. The report also includes cases outside traditional mass-tort litigation.
It therefore should not be treated as a complete census of mass-tort claimants or injuries. A large docket signals the scale of federal case management. It does not establish that the allegations are proven, predict an individual settlement, or show how many cases will reach trial.
Which active MDLs were the largest?
Johnson & Johnson talc remained the largest active transferred MDL, with 68,914 pending actions. Bard/Davol hernia mesh followed with 23,321, while AFFF/PFAS litigation had 15,246, according to the JPML's August 3 docket report. Other major product-liability dockets included Hair Relaxer with 11,779 actions, Proton-Pump Inhibitor No.
II with 11,321, and Bair Hugger with 8,407. These cases involve different products and alleged injuries, showing that the federal mass-tort caseload is not concentrated in one category. Depo-Provera ranked ninth with 6,294 pending actions. social Media Adolescent Addiction had 3,137, while the Covidien hernia-mesh MDL had 2,449 as of August 3.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Depo-Provera moved toward settlement—but litigation continues
The Depo-Provera MDL entered settlement administration after the parties said an agreement would give a substantial percentage of pending plaintiffs an opportunity to resolve their claims. On August 5, the Northern District of Florida appointed BrownGreer as settlement administrator in Case Management Order No. 13.
That appointment does not mean every plaintiff has settled or qualifies for an offer. Settlement administration can proceed while disputed scientific and legal issues remain before the court. The judge also scheduled a September 18 Rule 702 hearing concerning expert evidence. That hearing matters because decisions about proposed expert testimony can affect which arguments and evidence advance in the litigation.
Trials and opt-outs show why headline results have limits
Social Media Adolescent Addiction entered an important trial phase in August. The Northern District of California announced that live trial audio would begin August 18, giving the public greater access to the proceedings without determining how other pending actions will end. On August 4, a Boston federal jury awarded Larry and Tammy Patterson $88 million in the first Covidien hernia-mesh bellwether.
Reuters reported that Medtronic planned to challenge the verdict through post-trial motions and an appeal. One bellwether can influence negotiations, but it does not produce an automatic award for other plaintiffs. Paraquat shows the opposite complication: even a settlement process may leave substantial litigation behind. A Southern District of Illinois order reported significant opt-outs and authorized limited discovery in selected opt-out cases; 183 of 217 eligible Nachawati clients declined offers, according to the court's June 3 order.
What should plaintiffs and families watch next?
The most consequential near-term developments are specific court events, not changes in raw docket size: Anyone assessing a possible claim should identify the exact product, alleged injury, court docket, and filing status involved. Current plaintiffs can ask their lawyers whether a settlement process applies to them, whether they must make an election, and which deadlines control their individual cases. Do not assume that inclusion in an MDL guarantees settlement eligibility, or that a verdict in one bellwether determines the value or outcome of another plaintiff's claim.
- The September 18 Depo-Provera expert-evidence hearing.
- Trial developments following the August 18 start of live audio in the social-media litigation.
- Post-trial motions and any appeal challenging the Covidien verdict.
- Discovery and case selection involving Paraquat plaintiffs who rejected settlement offers.
You Might Also Like
- Mass Tort Market Update: Prices Demand and Regional Trends to Watch
- Mass Tort Policy Update: New Rules Proposals and Legal Questions Explained
- Mass Tort Forecast: What Could Happen Next After This Week’s News